On Nov 14, major Wall Street analysts update their ratings for $Natera (NTRA.US)$, with price targets ranging from $150 to $185.
Morgan Stanley analyst Tejas Savant maintains with a buy rating, and adjusts the target price from $132 to $176.
Goldman Sachs analyst Matthew Sykes maintains with a buy rating, and adjusts the target price from $140 to $160.
Jefferies analyst Tycho Peterson maintains with a buy rating, and adjusts the target price from $142 to $182.
TD Cowen analyst Daniel Brennan maintains with a buy rating, and maintains the target price at $175.
BTIG analyst Mark Massaro maintains with a buy rating, and adjusts the target price from $150 to $185.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
The reassessment of estimates for Natera, taking into account the Q3 results along with the revised outlook for 2024 and preliminary commentary on 2025 from the management discussion, supports the view that the stock's significant multiple is well warranted. This is due to several factors that are expected to contribute to both near-term and long-term upside in estimates, positioning the stock as a high-conviction selection.
Natera delivered another robust quarterly performance, according to an analyst. The company is achieving impressive results across various business aspects, such as volume, selling price, margin, and cash burn, with potential for continued enhancement through 2025. The company is considered one of the premier entities within the diagnostics sector.
Natera's Q3 results were exceptionally strong, as evidenced by the continuous improvement in its fundamentals. The company is channeling its operating cash flow back into the business, which is strengthening its position in sales, marketing, medical affairs, and legal aspects.
Natera recorded an impressive quarter with sales, margins, and cash flow that significantly exceeded expectations.
Natera's third quarter revenue and gross margins exceeded estimates, signaling a robust business momentum. This includes a significant 60% year-over-year growth in Signatera clinical volume and noteworthy gains in the women's health sector.
Here are the latest investment ratings and price targets for $Natera (NTRA.US)$ from 8 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月14日，多家華爾街大行更新了$Natera (NTRA.US)$的評級，目標價介於150美元至185美元。
摩根士丹利分析師Tejas Savant維持買入評級，並將目標價從132美元上調至176美元。
高盛集團分析師Matthew Sykes維持買入評級，並將目標價從140美元上調至160美元。
富瑞集團分析師Tycho Peterson維持買入評級，並將目標價從142美元上調至182美元。
TD Cowen分析師Daniel Brennan維持買入評級，維持目標價175美元。
BTIG分析師Mark Massaro維持買入評級，並將目標價從150美元上調至185美元。
此外，綜合報道，$Natera (NTRA.US)$近期主要分析師觀點如下：
對natera的估算重新評估，考慮到第三季度的結果以及針對2024年的修訂展望和管理層對2025年的初步評論，支持這一觀點：該股票的顯著倍數是非常合理的。這是由於預計將有多個因素爲估算的短期和長期上行貢獻，使該股票成爲一個高信心水平的選擇。
根據一位分析師的說法，natera交出了另一個強勁的季度表現。該公司在多個業務方面取得了令人印象深刻的成果，例如成交量、售價、利潤率和現金燃燒，並且到2025年還有繼續提升的潛力。該公司被認爲是診斷板塊內的頂尖企業之一。
natera的第三季度業績非常強勁，基本面的持續改善證明了這一點。該公司正在將其經營現金流再投入到業務中，這增強了其在銷售、市場營銷、醫療事務和法律方面的地位。
natera錄得了一個令人印象深刻的季度，銷售、利潤率和現金流大大超過預期。
natera的第三季度營業收入和毛利潤率超過了預測，預示着強勁的業務勢頭。這包括Signatera臨床成交量同比增長60%以及女性健康板塊的顯著提升。
以下爲今日8位分析師對$Natera (NTRA.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
